MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Principal demo aims ended up To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, when one of the exploratory https://nv-513843210.dailyblogzz.com/31439595/bcat-in-4-an-overview